ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

4D Pharma Research Ltd., a subsidiary of 4D Pharma Plc, is a British company located in Aberdeen that engages in research and experimental development on biotechnology.

BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 55 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. “Caring for your Health” is the Group’s motto, and strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce new medicines to the market over the next few years, strengthening its international presence.

Grape King Bio Ltd. engages in the production and sale of pharmaceutical preparations, patent medicine, liquid tonics, drinks, and healthy food. It operates through the following segments: Multi-Level Marketing (MLM), Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM). The MLM segment is involved in the direct seller of Pro-partner Inc., including the company’s development and manufacturing products for Pro-partner Inc., The Distributors segment include GRAPE KING BIO’s self-owned brand products. The ODM/OEM segment refers to the ODM/OEM in Taiwan and Shanghai. The company was founded by Shui Chao Tseng in 1971 and is headquartered in Taoyuan, Taiwan.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Advent Therapeutics, Inc. provides therapies for micro-orphan applications. It manufactures a product for curing a disorder in newborn infants in the ICU. The company is headquartered in Lumberville, PA.

PharmaIN is a development stage biopharmaceutical company focused on enabling and improving injectable therapeutics based on the Protected Graft Copolymer (PGC™), our patented and proprietary drug delivery technology licensed from Massachusetts General Hospital. We are focused on half-life extension and targeted delivery of proteins, peptides, siRNA, and potent small molecule therapeutics.

MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. They hope to achieve a healthspan expansion for patients: They want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people. MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.

The group's parent company, Xinghui Pharmaceuticals , was founded in Yilan in 1977. Since 1997, it has been overseas. It established a subsidiary in China, Canada- China CommScope Pharmaceutical Co. , Ltd. , to establish a US-Canada production and sales system. In 2002, it invested in “ Xinghui Tianli (Hangzhou) Pharmaceutical Co., Ltd. ” in the mainland ; Established " Xingguo New Drug Co. , Ltd. " in Yilan, Taiwan , and " Xingli Medical Equipment Biotech Co. , Ltd. " in 2012 .

Guangdong Leiyunshang Pharmaceutical Co., Ltd., established on 2011-01-27, Business scope includes production,Sales:large volume injection,small volume injection(Hormone),tablet(Hormone),hard capsule,Granules,pill(water pill,honey pill,Concentrated pills),mixture,oral liquid,tincture(Including external use),API,oral solution,Traditional Chinese medicine pretreatment and extraction workshop.(The above items are engaged in production and operation activities according to the production address of the drug production license)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Suzhou Kaixiang Biotechnology Co., Ltd., established on 2010-12-03, The scope of business includes biological fields and instruments,food additives,Technical development of plant extracts and active ingredients,technology transfer,Technical consulting and related technical services;cosmetic,Chemical raw materials and products(In addition to dangerous goods),Instrument purchase and sale;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:food business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

Link Health Group Ltd. is a Chinese private company located in Guangzhou that manufactures pharmaceutical and medical device products.\nThe company says this about itself: Link Health Group, Ltd. is a leading Chinese pharmaceutical company whose focus is based on innovation discovery and development of drugs for unmet medical needs. The company is based in South China and currently has a pipeline covering 9 innovative drugs under development. Link Health has its know-how center established since early this year in Amsterdam, Netherlands, and a satellite office in UK. The Headquarter in China will remain its function for operation including registration, development, manufacturing and distributions.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. engages in the manufacture, sale, research and development of household products and medical equipment. It also develops, manufactures, markets, and sells electro-medical equipment in the patient monitoring, laboratory instrument, and medical ultrasound fields. The company was founded by Hang Xu on January 25, 1991 and is headquartered in Shenzhen, China.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.